1801 Panoramica delle azioni Innovent Biologics, Inc. è una società biofarmaceutica che sviluppa e commercializza anticorpi monoclonali e altri farmaci nei settori dell'oncologia, dell'oftalmologia, delle malattie autoimmuni, cardiovascolari e metaboliche nella Repubblica Popolare Cinese. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Innovent Biologics, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Innovent Biologics Prezzi storici delle azioni Prezzo attuale dell'azione HK$35.20 Massimo di 52 settimane HK$52.15 Minimo di 52 settimane HK$28.30 Beta 0.24 Variazione di 1 mese -8.57% Variazione a 3 mesi -17.37% Variazione di 1 anno -8.09% Variazione a 3 anni -28.74% Variazione a 5 anni n/a Variazione dall'IPO -38.35%
Notizie e aggiornamenti recenti
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Co-Founder recently sold HK$81m worth of stock Oct 05
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26 Vedi altri aggiornamenti
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Co-Founder recently sold HK$81m worth of stock Oct 05
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Aug 29
Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China Aug 22
The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert Aug 21
Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) Aug 02
the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc Aug 01
Forecast to breakeven in 2025 Jul 22
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions Jun 25
High number of new directors Jun 01
Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA May 29
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 May 23
Co-Founder recently sold HK$37m worth of stock May 12
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer May 08
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) May 01
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer Apr 30
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application Apr 02
Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024 Mar 21
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) Mar 21
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Mar 07
Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer Mar 06
Now 25% undervalued after recent price drop Mar 02
Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 01
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease Feb 20
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee Feb 10
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China Feb 07 Innovent Biologics, Inc. Announces Chief Financial Officer Changes Feb 05
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints Jan 09
China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib Dec 19
Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications Dec 18
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Dec 08
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351 Nov 25
Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib Nov 23
Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care Nov 22
The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients Nov 18
Now 20% undervalued Nov 03
Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity Oct 30
Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor) Sep 29
Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 21 Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 20
New minor risk - Shareholder dilution Sep 20
First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022) Aug 24
National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo Aug 17
Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Aug 08 IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting Jun 12 Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC Jun 05
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Jun 03
Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint May 11
Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy May 10
Full year 2022 earnings released: CN¥1.46 loss per share (vs CN¥2.16 loss in FY 2021) Mar 29
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Feb 16
Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy Feb 15
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications Jan 19
Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Jan 10
Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib Jan 06
Forecast to breakeven in 2025 Dec 31 Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Dec 05
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity Nov 15
Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022 Nov 07
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors Oct 31
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 19
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 17 Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.69 loss in 1H 2021) Oct 01
Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study Sep 08
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 07
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 06
No longer forecast to breakeven Aug 27
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.81 loss in 1H 2021) Aug 26
Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies Aug 24
Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) Aug 18
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint Aug 11
Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema Aug 08 Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V. Aug 05
Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy Aug 01 Rendimenti per gli azionisti 1801 HK Biotechs HK Mercato 7D -5.9% -3.9% -0.5% 1Y -8.1% -5.7% 19.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 1801 ha avuto una performance inferiore rispetto al Hong Kong Biotechs che ha registrato un rendimento -5.7 % nell'ultimo anno.
Rendimento vs Mercato: 1801 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 19.9 % nell'ultimo anno.
Volatilità dei prezzi Is 1801's price volatile compared to industry and market? 1801 volatility 1801 Average Weekly Movement 8.5% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Prezzo delle azioni stabile: 1801 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di 1801 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Innovent Biologics, Inc. è una società biofarmaceutica che sviluppa e commercializza anticorpi monoclonali e altri farmaci nei settori dell'oncologia, dell'oftalmologia, delle malattie autoimmuni, cardiovascolari e metaboliche nella Repubblica Popolare Cinese. L'azienda offre Tyvyt, un anticorpo monoclonale umano anti-PD-1; BYVASDA, un anticorpo monoclonale anti-VEGF completamente umano; HALPRYZA, un anticorpo monoclonale chimerico murino/umano anti-CD20 ricombinante; SULINNO, un anticorpo monoclonale anti-TNF-a completamente umano; Pemazyre, un inibitore selettivo di FGFR; Olverembatinib, un nuovo TK di BCR-ABL; Cyramza, un antagonista del recettore 2 di VEGF; e Retsevmo, un inibitore selettivo e potente della RET chinasi. L'azienda sta inoltre sviluppando IBI-326, una terapia con cellule T CAR BCMA completamente umane; IBI-376, un inibitore orale di PI3Kd; IBI-351, un inibitore di KRASG12C; IBI-344, un inibitore della tirosin-chinasi repressore del silenziamento 1/TRK; IBI-126, un ADC mirato a CEACAM5; IBI-306, un nuovo anticorpo monoclonale anti-proteina convertasi subtilisina/kexina di tipo 9; IBI-362, un doppio agonista del recettore del glucagone peptide-1 e del recettore del glucagone; e IBI-112, un nuovo anti-IL-23 a lunga durata d'azione.
Mostra di più Innovent Biologics, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Innovent Biologics con la sua capitalizzazione di mercato? 1801 statistiche fondamentali Capitalizzazione di mercato HK$57.65b Guadagni(TTM ) -HK$1.37b Ricavi(TTM ) HK$7.95b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 1801 Conto economico (TTM ) Ricavi CN¥7.46b Costo del fatturato CN¥2.12b Profitto lordo CN¥5.34b Altre spese CN¥6.62b Guadagni -CN¥1.28b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.78 Margine lordo 71.58% Margine di profitto netto -17.18% Rapporto debito/patrimonio netto 25.8%
Come si è comportato 1801 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/21 16:25 Prezzo dell'azione a fine giornata 2024/12/20 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Innovent Biologics, Inc. è coperta da 53 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Bo Li BofA Global Research
Mostra 50 altri analisti 
